Thioxothiazolidine derivative having Ras function inhibitory effect
申请人:Kataoka Tohru
公开号:US09056862B2
公开(公告)日:2015-06-16
The present invention provides an anticancer drug having a Ras function inhibitory action.
The present invention provides a Ras function inhibitor comprising a compound represented by the formula (I′):
wherein each symbol is as defined in the present specification, or a salt thereof.
[EN] FUSED RING COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES<br/>[FR] COMPOSÉS CYCLIQUES FUSIONNÉS UTILES EN TANT QU'INHIBITEURS DE TYROSINE KINASES FGFR
申请人:NUTSHELL BIOTECH SHANGHAI CO LTD
公开号:WO2022193227A1
公开(公告)日:2022-09-22
The present disclosure relates to thia-tricyclic compounds, and pharmaceutical compositions including the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases.
Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
申请人:Pfizer Products Inc.
公开号:EP1006113A1
公开(公告)日:2000-06-07
The present invention relates to compounds of the formula
wherein R1, R2, R3 and R4 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula I and to methods of inhibiting abnormal cell growth, including cancer, in a mammal by administering the compounds of Formula I to said mammal.
本发明涉及如下式的化合物
其中 R1、R2、R3 和 R4 如本文所定义。本发明还涉及含有式 I 化合物的药物组合物,以及通过向哺乳动物施用式 I 化合物来抑制哺乳动物体内异常细胞生长(包括癌症)的方法。